MX2018005376A - Derivados de azetidina para formacion de imágenes de tau. - Google Patents

Derivados de azetidina para formacion de imágenes de tau.

Info

Publication number
MX2018005376A
MX2018005376A MX2018005376A MX2018005376A MX2018005376A MX 2018005376 A MX2018005376 A MX 2018005376A MX 2018005376 A MX2018005376 A MX 2018005376A MX 2018005376 A MX2018005376 A MX 2018005376A MX 2018005376 A MX2018005376 A MX 2018005376A
Authority
MX
Mexico
Prior art keywords
tau imaging
azetidine derivatives
tau
imaging
compound
Prior art date
Application number
MX2018005376A
Other languages
English (en)
Inventor
Xiong Hui
Attardo Giorgio
Horchler Carey
Ghosh Shyamali
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2018005376A publication Critical patent/MX2018005376A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0444—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un nuevo compuesto de la fórmula: métodos de preparación de este compuesto, métodos de uso de este compuesto para imágenes tau y preparaciones de formulaciones de formación de imágenes de tau.
MX2018005376A 2015-11-13 2016-11-04 Derivados de azetidina para formacion de imágenes de tau. MX2018005376A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562254906P 2015-11-13 2015-11-13
PCT/US2016/060621 WO2017083198A1 (en) 2015-11-13 2016-11-04 Azetidine derivatives for tau imaging

Publications (1)

Publication Number Publication Date
MX2018005376A true MX2018005376A (es) 2018-08-01

Family

ID=57389526

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005376A MX2018005376A (es) 2015-11-13 2016-11-04 Derivados de azetidina para formacion de imágenes de tau.

Country Status (19)

Country Link
US (1) US10301308B2 (es)
EP (1) EP3374358B1 (es)
JP (1) JP2018531978A (es)
KR (1) KR20180061364A (es)
CN (1) CN108290883B (es)
AU (1) AU2016351609B2 (es)
BR (1) BR112018006969B1 (es)
CA (1) CA3003884C (es)
DK (1) DK3374358T3 (es)
EA (1) EA034018B1 (es)
ES (1) ES2864825T3 (es)
HK (1) HK1257042A1 (es)
IL (1) IL258313B (es)
MX (1) MX2018005376A (es)
PL (1) PL3374358T3 (es)
PT (1) PT3374358T (es)
SA (1) SA518391527B1 (es)
WO (1) WO2017083198A1 (es)
ZA (1) ZA201802526B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150483A1 (en) * 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1574500A1 (en) * 2002-12-16 2005-09-14 BF Research Institute, Inc. Quinoline derivative as diagnostic probe for disease with tau protein accumulation
PT2247558T (pt) 2008-02-14 2022-03-21 Lilly Co Eli Novos agentes de imagiologia para deteção de disfunção neurológica
WO2010078370A1 (en) * 2008-12-31 2010-07-08 Avid Radiopharmaceuticals, Inc. Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
CN104781234A (zh) 2012-05-22 2015-07-15 伊莱利利公司 用于检测神经功能障碍的基于咔啉和咔唑的成像剂

Also Published As

Publication number Publication date
BR112018006969B1 (pt) 2022-04-26
DK3374358T3 (da) 2021-03-08
US20180282322A1 (en) 2018-10-04
PL3374358T3 (pl) 2021-07-12
AU2016351609B2 (en) 2019-08-08
IL258313B (en) 2021-04-29
SA518391527B1 (ar) 2021-02-07
CN108290883B (zh) 2021-02-09
US10301308B2 (en) 2019-05-28
EP3374358A1 (en) 2018-09-19
PT3374358T (pt) 2021-03-31
EP3374358B1 (en) 2021-02-17
CA3003884C (en) 2020-04-21
AU2016351609A1 (en) 2018-04-19
HK1257042A1 (zh) 2019-10-11
ES2864825T3 (es) 2021-10-14
IL258313A (en) 2018-05-31
KR20180061364A (ko) 2018-06-07
CN108290883A (zh) 2018-07-17
ZA201802526B (en) 2019-10-30
JP2018531978A (ja) 2018-11-01
EA034018B1 (ru) 2019-12-19
WO2017083198A1 (en) 2017-05-18
CA3003884A1 (en) 2017-05-18
EA201890799A1 (ru) 2018-10-31
BR112018006969A2 (pt) 2018-10-16

Similar Documents

Publication Publication Date Title
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
PH12018500034A1 (en) Bicyclic lactams and methods of use thereof
PH12018500457A1 (en) New phenoxymethyl derivatives
WO2017124002A8 (en) Multispecific immunomodulatory antigen-binding constructs
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
AU2015352440B2 (en) Compounds
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
PH12016501613B1 (en) Pyrazines modulators of gpr6
MX2016003725A (es) Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau.
MX369451B (es) Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas.
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
MX2016015298A (es) Inhibidores de nampt y metodos.
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
MX2018005376A (es) Derivados de azetidina para formacion de imágenes de tau.
IN2014MU00859A (es)
MX2018010652A (es) Composiciones farmaceuticas.
MX2016013428A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
IN2014MU01194A (es)